Evaluation of Health Care Reform Impact on Cancer Patients` Access To Medicine: A Pilot-Center Experience in Islamic Republic of Iran

Abstract

A879 from 90.1% (1L) and 87.5% (2L) APACs could be decoded. Most used drug combinations reported for 1L-treatment were cyclophosphamide monotherapy (8.6%), cycl ophosphamide+dexamethasone+thalidomide (7.7%) and melphalane+prednisone (4.9%); for 2L-treatment, cyclophosphamide monotherapy (9.7%), bortezomibe (6.3%) cyclophosphamide+dexamethasone+thalidomide (5.2%) were the most frequent. ConClusions: The most reported drug was a monotherapy not included in the PCDT recommendations, all other frequent combinations were coherent with the current PCDT. The results found are limited by the uncertainty in data input in the database.